Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
101010.pl is one of the many independent Mastodon servers you can use to participate in the fediverse.
101010.pl czyli najstarszy polski serwer Mastodon. Posiadamy wpisy do 2048 znaków.

Administered by:

Server stats:

496
active users

101010.pl: AboutStatusProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.4.0-alpha.5

#covidbrain

1 post1 participant0 posts today
Tom Kindlon

News Release:
Disrupting the residual triggers of COVID-19 in patients with #longCOVID: Spatial transcriptomics reveals activation of #SARSCoV2 -related signaling pathways in the epipharynx of patients with long COVID

eurekalert.org/news-releases/1

Includes discussion of a treatment

@longcovid
#PASC #PwLC #postcovid #postcovid19 #Covidlonghaulers #PostCovidSyndrome #longhaulers #COVIDBrain #NeuroPASC
@covid19 #Coronavirus
#COVID19 #COVID #COVID_19 #COVIDー19 #CovidIsNotOver
@auscovid19 #auscovid19

Tom Kindlon

"the results from this analysis suggest among people who were tested for #COVID19, those with a positive test experienced an increased rate of diagnosis of infectious illnesses in the 12 months following"

thelancet.com/journals/laninf/

Image is from latest Science for ME weekly update

@longcovid
#LongCovid #PASC #PwLC #postcovid #postcovid19 #LC #Covidlonghaulers #PostCovidSyndrome #longhaulers #COVIDBrain #NeuroPASC
@covid19 #Coronavirus
#COVID #COVID_19 #COVIDー19 #SARSCoV2
@auscovid19 #auscovid19

Tom Kindlon

From the Solve ME/CFS Initiative

People w/ #LongCovid may participate in a new clinical trial testing whether the drug baricitinib improves neurocognitive function & other functions diminished by Long Covid. Learn more about the trial led by Dr. Wesley Ely of
the Vanderbilt University Medical Center here:
ow.ly/paS250UOeWv

@longcovid
#PwLC #PostCovidSyndrome #LC #PASC #postcovid
#CovidBrain
@covid19 #COVIDー19 #COVID19 #COVID #COVID_19 #SARSCoV2

Solve ME/CFS Initiative · New Clinical Trial Will Test How Baricitinib Improves Neurocognitive Function in Patients with Long Covid - Solve ME/CFS InitiativePatients with Long Covid may participate in an important new clinical trial—the REVERSE-LC trial (Evaluating Baricitinib on Persistent Neurologic and Cardiopulmonary Symptoms of Long COVID)—which will test whether the drug baricitinib improves neurocognitive function and other functions severely diminished by Long Covid.
Tom Kindlon

New:
Digital health app data reveals an effect of ovarian hormones on long COVID and myalgic encephalomyelitis symptoms

medrxiv.org/content/10.1101/20

"Menstruation is associated with worsened symptoms in long COVID and ME/CFS"

@mecfs
#MyalgicEncephalomyelitis #ChronicFatigueSyndrome #MEcfs #CFS #PwME #MyalgicE Hashtags:
@longcovid
#LongCovid #PASC #PwLC #postcovid #postcovid19 #LC #Covidlonghaulers #PostCovidSyndrome #longhaulers #COVIDBrain #NeuroPASC

Tom Kindlon

Person in Switzerland (on Reddit):

Neurologist: "before the pandemic, his whole team of 3 people, who deal with the ME/CFS cases here, treated 10 patients PER YEAR. Now, after Covid19, he alone sees 5 patients PER WEEK to determine and/or treat patients for ME/CFS"

@mecfs
#MyalgicEncephalomyelitis #ChronicFatigueSyndrome #MEcfs #CFS #PwME @longcovid
#LongCovid #PASC #PwLC #postcovid #postcovid19 #LC #Covidlonghaulers #PostCovidSyndrome #longhaulers #COVIDBrain #NeuroPASC

Continued thread
Tom Kindlon

2/
Blog post on this study "#COVID19 Triggers ME/CFS" by Suzanne D. Vernon, PhD

batemanhornecenter.org/covid-1

"531 participants met ME/CFS criteria, translating to a prevalence of 4.5% among those infected—nearly 8 times higher than uninfected participants"

@mecfs #MyalgicEncephalomyelitis #MEcfs #CFS #PwME @longcovid
#LongCovid #PASC #PwLC #postcovid #postcovid19 #LC #longhaulers #COVIDBrain #NeuroPASC
@covid19 #Coronavirus
#COVID #COVID_19 #COVIDー19 #SARSCoV2 @novid@chirp.social #novid @novid@a.gup.pe #auscovid19

Tom Kindlon

New US research

Incidence & Prevalence of Post‑COVID‑19 Myalgic Encephalomyelitis:A Report from the Observational
RECOVER‑Adult Study

link.springer.com/article/10.1

"ME/CFS is a diagnosable sequela that develops at an increased rate following SARS-CoV-2 infection"

@mecfs
#MyalgicEncephalomyelitis #MEcfs #CFS #PwME @longcovid
#LongCovid #PASC #PwLC #postcovid #postcovid19 #LC #longhaulers #COVIDBrain
@covid19 #Coronavirus
#COVID19 #COVID #SARSCoV2 @novid@chirp.social #novid @novid@a.gup.pe #CovidIsNotOver
@auscovid19

Tom Kindlon

Omics-based analysis of mitochondrial dysfunction & BBB integrity in #postCOVID -19 sequelae

nature.com/articles/s41598-024

"By analysing the multi-transcriptome data, this work explores the neurological impacts of the #SARSCoV2 virus and provides insight into the molecular mechanisms behind BBB breakdown and neurological symptoms in #COVID19 patients”

@longcovid
#LongCovid #PwLC #LC #PASC #CovidBrain #NeuroPASC
@covid19 @novid #novid #auscovid19

NatureOmics-based analysis of mitochondrial dysfunction and BBB integrity in post-COVID-19 sequelae - Scientific ReportsThe SARS-CoV-2 virus that resulted in the COVID-19 pandemic has been implicated in a range of neurological issues, such as encephalopathy, stroke, and cognitive decline. Although the precise mechanism causing these issues is unknown, mounting evidence shows that blood–brain barrier (BBB) disruption is probable2 a major factor. The integrity of the blood–brain barrier (BBB), a highly selective barrier that divides the brain from the systemic circulation, is crucial for preserving normal brain function. By analysing the multi-transcriptome data, this work explores the neurological impacts of the SARS-CoV-2 virus and provides insight into the molecular mechanisms behind BBB breakdown and neurological symptoms in COVID-19 patients. The endothelial cells of BBB expresses inflammatory genes in response to the systemic inflammation induced due to SARS-CoV-2 remnants in the body. This raises the possibility that systemic inflammation brought on by SARS-CoV-2 and BBB integrity are correlated. Furthermore, the study highlights the pathways involved in oxidative stress and endothelial cell activation, revealing their role in COVID-19 passage through BBB and induction of systemic inflammation and advancement toward neurological disorders. The article showcases the evidence that mitochondrial dysfunction is a major aftermath associated with SARS-CoV-2 infection as the impaired Mitochondria leads to an accumulation of reactive oxygen species (ROS), triggering endothelial dysfunction, and leading to the passage of harmful molecules across the BBB. This study offers insightful information that may open up the possibilities for new treatment plans by targeting biomarkers specifically associated with inflammation and BBB dysfunctioning conditions.
Tom Kindlon

#PostCOVID19 Vaccination & #LongCOVID : Insights from Patient-Reported Data

mdpi.com/2076-393X/12/12/1427

"This study analyzed 2 independent #PASC cohorts found most individuals with PASC did not report a subjective change in their PASC symptoms after receiving post-COVID-19 vaccination(s)”

@longcovid
#PwLC #PostCovidSyndrome #LC #postcovid
#CovidBrain
@covid19 #COVIDー19 #COVID19 #COVID #COVID_19 #SARSCoV2 #novid @novid #CovidIsNotOver #auscovid19

MDPIPost-COVID-19 Vaccination and Long COVID: Insights from Patient-Reported DataIntroduction: COVID-19 vaccinations reduce the severity and number of symptoms for acute SARS-CoV-2 infections and may reduce the risk of developing Long COVID, also known as post-acute sequelae of SARS-CoV-2 (PASC). Limited and heterogenous data exist on how these vaccinations received after COVID-19 infection might impact the symptoms and trajectory of PASC, once persistent symptoms have developed. Methods: We investigated the association of post-COVID-19 vaccination with any SARS-CoV-2 vaccine(s) on PASC symptoms in two independent cohorts: a retrospective chart review of self-reported data from patients (n = 128) with PASC seen in the Stanford PASC Clinic between May 2021 and May 2022 and a 2023 multinational survey assessment of individuals with PASC (n = 484). Findings: Within the PASC Clinic patient cohort (n = 128), 58.6% (n = 75) were female, and 41.4% (n = 53) were male; 50% (n = 64) were white, and 38.3% (n = 49) were non-white. A total of 60.2% (n = 77) of PASC Clinic patients reported no change in their PASC symptoms after vaccination, 17.2% (n = 22) reported improved symptoms, and 22.7% (n = 29) reported worsened symptoms. In the multinational survey cohort (n = 484), 380 were from the U.S., and 104 were from outside the U.S.; 88.4% (n = 428) were female, and 11.6% (n = 56) were male; and 88.8% (n = 430) were white, and 11.2% (n = 54) were non-white. The distribution of survey self-reported vaccine effects on PASC symptoms was 20.2% worsened (n = 98), 60.5% no effect (n = 293), and 19.2% improved (n = 93). In both cohorts, demographic features, including age, sex, and race/ethnicity, were not significantly associated with post-vaccination PASC symptom changes. There was also a non-significant difference in the median dates of COVID-19 infection among the different outcomes. BMI was significant for symptom improvement (p = 0.026) in the PASC Clinic cohort, while a history of booster doses was significant for symptom improvement (p < 0.001) in the survey cohort. Conclusions: Most individuals with PASC did not report significant changes in their overall PASC symptoms following COVID-19 vaccinations received after PASC onset. Further research is needed to better understand the relationship between COVID-19 vaccinations and PASC.
ExploreLive feeds
About